Generation and characterization of the Eµ-Irf8 mouse model.

Area of Science:

• * Hematologic Oncology
• * Molecular Biology
• * Immunology

Background:

• * Chromosomal translocations in mature B-cell malignancies frequently involve oncogenes juxtaposed to immunoglobulin regulatory regions.
• * The t(14;16) translocation in diffuse large B-cell lymphoma (DLBCL) targets the transcription factor IRF8, which is also mutated in ~10% of DLBCLs.
• * IRF8's role in myeloid/dendritic cells is known, but its specific contribution to mature B-cell malignancies remains unclear.

Purpose of the Study:

• * To investigate the role of IRF8 deregulation in B-cell lymphomagenesis.
• * To generate and characterize a mouse model (Eµ-Irf8) mimicking IRF8 deregulation seen in DLBCL.

Main Methods:

• * Generation of the Eµ-Irf8 transgenic mouse model.
• * Analysis of B-cell development and populations in bone marrow and spleen.
• * Assessment of gene expression for known IRF8 targets (Aicda, Bcl6) in mature B-cells.
• * Monitoring of lymphoma incidence and survival rates in Eµ-Irf8 mice compared to wild-type (WT) controls.

Main Results:

• * Eµ-Irf8 mice exhibited normal development and peripheral blood parameters.
• * Accumulation of pre-pro-B-cells and transitional B-cells was observed in Eµ-Irf8 mice.
• * Overexpression of lymphomagenic IRF8 targets, Aicda and Bcl6, occurred in mature B-cells.
• * No significant increase in B-cell lymphoma incidence was detected in Eµ-Irf8 mice, despite reduced survival.

Conclusions:

• * IRF8 deregulation, as modeled in Eµ-Irf8 mice, impacts B-cell development but does not fully drive lymphomagenesis on its own.
• * The observed phenotype suggests incomplete penetrance of IRF8's pro-lymphoma effects.
• * A second genetic hit may be required to fully manifest the oncogenic potential of IRF8 in B-cell malignancies.